Article Contents ::
- 1 The Brand Name PZYCADILA-A T I Has Generic Salt :: COAGULATION
- 2 PZYCADILA-A T I Is From Company Pharmacia Priced :: Rs. 6490
- 3 PZYCADILA-A T I have COAGULATION is comes under Sub class #N/A of Main Class #N/A
- 4 Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name PZYCADILA-A T I Has Generic Salt :: COAGULATION
PZYCADILA-A T I Is From Company Pharmacia Priced :: Rs. 6490
PZYCADILA-A T I have COAGULATION is comes under Sub class #N/A of Main Class #N/A
Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
|COAGULATION||V INJ||Rs. 6490||INJ|
Indications for Drugs ::
Hemophilia B or Christmas disease
Drug Dose ::
In adult PTPs, on average, one international unit of coagulation factor ix recombinant per kilogram of body weight increased the circulating activity of factor IX by 0.8 ± 0.2 (range 0.4 to 1.4) IU/dL. In pediatric patients, on average, one international unit of coagulation factor ix recombinant per kilogram of body weight increased the circulating activity of factor IX by 0.7 ± 0.3 (range 0.2 to 2.1 IU/dL; median of 0.6 IU/dL per IU/kg).
patients with a known history of hypersensitivity to hamster protein.
Drug Precautions ::
Activity-neutralizing antibodies (inhibitors) have been detected in patients receiving factor IXcontaining products. As with all factor IX products, patients using (coagulation factor ix recombinant) should be monitored for the development of factor IX inhibitors . Patients with factor IX inhibitors may be at an increased risk of anaphylaxis upon subsequent challenge with factor IX. Patients experiencing allergic reactions should be evaluated for the presence of inhibitor. Preliminary information suggests a relationship may exist between the presence of major deletion mutations in a patient’s factor IX gene and an increased risk of inhibitor formation and of acute hypersensitivity reactions. Patients known to have major deletion mutations of the factor IX gene should be observed closely for signs and symptoms of acute hypersensitivity reactions, particularly during the early phases of initial exposure to product. In view of the potential for allergic reactions with factor IX concentrates, the initial (approximately 10 – 20) administrations of factor IX should be performed under medical supervision where proper medical care for allergic reactions could be provided.
Drug Side Effects ::
fever or chills; continued bleeding after treatment; feeling like you might pass out; sudden numbness or weakness, especially on one side of the body; sudden headache, confusion, problems with vision, speech, or balance; or swelling in your feet or ankles, weight gain, loss of appetite. Less serious side effects may be more likely to occur, such as: headache; warmth, redness, or tingly feeling under your skin; nausea, vomiting; dizziness; or pain, redness, or swelling where the medicine was injected.
Pregnancy category ::
Drug Mode of Action ::
Factor IX is used as replacement therapy in patients with haemophilia B whereby there is a genetic deficiency of factor IX.
Drug Interactions ::